Lantheus (NASDAQ:LNTH) Given Hold Rating at Truist Financial

Lantheus (NASDAQ:LNTH)‘s stock had its “hold” rating reissued by analysts at Truist Financial in a report released on Monday,Benzinga reports. They presently have a $61.00 price target on the medical equipment provider’s stock, down from their prior price target of $63.00. Truist Financial’s price target points to a potential upside of 21.02% from the stock’s previous close.

A number of other brokerages have also weighed in on LNTH. Mizuho reduced their target price on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. TD Cowen cut their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. Finally, Weiss Ratings downgraded Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Lantheus has an average rating of “Hold” and an average target price of $74.17.

Lantheus Stock Down 1.3%

Shares of LNTH traded down $0.67 on Monday, hitting $50.41. The company’s stock had a trading volume of 374,209 shares, compared to its average volume of 1,256,816. The firm’s fifty day moving average price is $54.09 and its 200-day moving average price is $68.27. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $3.43 billion, a price-to-earnings ratio of 13.41 and a beta of 0.04.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $92.51 million for the quarter. On average, equities research analysts expect that Lantheus will post 6.01 EPS for the current year.

Insider Buying and Selling

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 6,812,000 shares of company stock worth $382,427,380. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after buying an additional 115,338 shares during the period. Westfield Capital Management Co. LP grew its position in shares of Lantheus by 2.2% in the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock valued at $155,101,000 after purchasing an additional 34,052 shares during the last quarter. Reinhart Partners LLC. increased its stake in shares of Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after purchasing an additional 197,719 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Lantheus by 2.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after purchasing an additional 31,454 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Lantheus in the 3rd quarter valued at $65,654,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.